Evidence map›Paper›PMID 40459043›Full record

ReviewFuture oncology (London, England)2026

Review of potential anti-cancer properties of lactobacilli against breast cancer.

Elnaz Ghorbani, Asma Afshari, Amir Avan, Majid Khazaei, Saman Soleimanpour

Abstract readReview
In one paragraph

Review in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elnaz GhorbaniDepartment of Medical Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Asma AfshariDepartment of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Saman SoleimanpourDepartment of Medical Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is one of the leading cause of mortality among females worldwide. Regarding the side effects of current therapeutics, the development of novel target-specific treatments is a priority. Probiotic bacteria, as nutraceuticals, have shown anti-cancer potential, supported by cell culture-based and animal model studies. There are studies indicating differences in gut and breast microbiota between healthy individuals and cancerous patients. Given the immunomodulatory and regulatory effects of probiotics on hormone-mediated pathways, the consumption of probiotics can be considered a safe approach in breast cancer management. This review summarizes the recent research on the potential therapeutic roles of

Indexed as

Breast NeoplasmsLactobacillusProbioticsAnimalsFemaleGastrointestinal MicrobiomeHumansapoptosisBreast cancerimmune responseinflammationLactobacillusmicrobiotaprobiotics

Identifiers

PMID40459043
PMCPMC12915824

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.